Beacon Pharmaceuticals PLC announcements
252 Dhaka Stock Exchange announcements for Beacon Pharmaceuticals PLC (BEACONPHAR) since 2010: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2025 (21).
- Appointment of Managing Director
The Company has informed that Mr. Ulfat Karim, Existing Chief Operating Offer (COO) and Director has been appointed as Managing Director of the Company effective from December 14, 2025.
- Credit Rating Result
Credit Rating Agency of Bangladesh Limited (CRAB) has announced the Surveillance rating of the Company as "AA3" in the long term and "ST-2" in the short term along with Stable outlook based on audited financial statements up to June 30, 2025; latest bank liability position and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record Date
Trading of the shares of the company will resume on 17.11.2025.
- Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 16.11.2025.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 2.26 for July-September 2025 as against Tk. 1.56 for July-September 2024. NOCFPS was Tk. 1.35 for July-September 2025 as against Tk. 2.96 for July-September 2024. NAV per share was Tk. 31.12 as on September 30, 2025 and Tk. 28.86 as on June 30, 2025.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 12.11.2025 to 13.11.2025 and trading of the shares will remain suspended on record date i.e., 16.11.2025.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 11, 2025 at 3:00 PM to consider, among others, Un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
- Dividend Declaration
The Board of Directors has recommended 21% Cash Dividend to General Shareholders (excluding Sponsors and Directors) for the year ended June 30, 2025. The Sponsors and Directors hold 92,084,615 shares out of the total 231,000,000 shares of the company and Cash Dividend payable to the General Shareholders is Tk. 291,722,309.00. Date of AGM: 23.12.2025, Time: 11:00 AM, Venue/Mode: Hybrid Platform. Record Date: 16.11.2025. (cont.) (Cont. News of BEACONPHAR): The Company has also reported EPS of Tk. 4.10, NAV per share of Tk. 28.86 and NOCFPS of Tk. 6.93 for the year ended June 30, 2025 as against Tk. 2.26, Tk. 26.37 and Tk. (0.78) respectively for the year ended June 30, 2024. (end)
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (23.10.2025) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2025 at 3:30 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
- Query Response
In response to the DSE query dated August 26, 2025, the company has informed that there is no undisclosed price sensitive information of the company for recent unusual price hike and increase in volume of shares.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.28 for January-March 2025 as against Tk. (0.95) for January-March 2024; EPS was Tk. 3.75 for July 2024-March 2025 as against Tk. 2.38 for July 2023-March 2024. NOCFPS was Tk. 5.45 for July 2024-March 2025 as against Tk. (7.38) for July 2023-March 2024. NAV per share was Tk. 27.80 as on March 31, 2025 and Tk. 26.37 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
- Clarification on recent news published in newspaper
In response to a DSE query letter to the company regarding a news published in a newspaper titled "Beacon Pharma tricked general shareholders" on March 27, 2025, the company has informed DSE the following: "With reference to your letter no. DSE/Listing/391/2025/1900, dated March 27, 2025, we would like to provide the following clarification regarding the recent news published in The Daily Star. Beacon Pharmaceuticals PLC (cont.1) (Cont. news of BEACONPHAR): Regarding the sale of products to Beacon Medicare Limited, we would like to confirm that such transactions are part of our strategic and technical collaborations, and they are carried out in full compliance with the applicable regulations of the Exchange." (end) (Cont. news of BEACONPHAR): has always remained committed to complying with the regulatory requirements of Dhaka Stock Exchange PLC. As a publicly listed company, we consistently publish our Financial Statements and Price Sensitive information (PSI) on a quarterly basis. In addition, our Annual Report provides a comprehensive overview of the company's financial performance, strategies, and other relevant disclosures. (cont.2)
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
- Category Change
The Company will be placed in 'A' category from existing 'Z' category with effect from February 06, 2025 as the Company has reported disbursement of 20% Cash Dividend to General Shareholder and 10% Cash Dividend to Sponsor Shareholder and Directors for the year ended June 30, 2024.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase the securities of Beacon Pharmaceuticals PLC in between 1st to 7th trading days following the change of categorization, with effect from February 06, 2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Category Change
The Company has been placed in 'Z' category from existing 'A' category with effect from today i.e., 04.02.2025 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024 regarding non-disbursement of the approved dividend within the stipulated time frame.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase securities of Beacon Pharmaceuticals PLC with effect from today i.e., 04.02.2025 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 1.91 for October-December 2024 as against Tk. 1.65 for October-December 2023; EPS was Tk. 3.47 for July-December 2024 as against Tk. 3.25 for July-December 2023. NOCFPS was Tk. 6.38 for July-December 2024 as against Tk. (2.34) for July-December 2023. NAV per share was Tk. 28.23 as on December 31, 2024 and Tk. 26.37 as on June 30, 2024.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2025 at 3:15 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.